To the Editor {#s1}
=============

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19) has reached a pandemic level. In a recent retrospective cohort study of COVID-19, comorbidities such as diabetes and hypertension were present in nearly half of patients \[[@R01]\]. The odds of in-hospital death were significantly higher in patients with diabetes (2.85) and hypertension (3.05) \[[@R01]\].

It remains unknown why the prevalence of diabetes and hypertension is high in COVID-19 patients and why such diseases can be risk for severe COVID-19 including death.

To elucidate such clinical questions, I searched the prevalence of diabetes and hypertension and the controlling status of such diseases in all COVID-19 patients, severe and non-severe COVID-19 patients using PubMed. The prevalence of each disease in severe and non-severe COVID-19 patients was meta-analyzed by Peto's exact method, and odds ratio (OR) with 95% confidence interval (CI) was shown.

The prevalence of diabetes in all COVID-19 patients, severe and non-severe COVID-19 patients were shown in [Table 1](#T1){ref-type="table"} \[[@R01]-[@R12]\]. Half of studies showed a statistically significantly higher prevalence of diabetes in severe patients than in non-severe patients. In the meta-analysis, the prevalence of diabetes in severe patients was significantly higher than that in non-severe patients (OR: 3.52, 95% CI: 2.65 - 4.67). Unfortunately, only three studies were available to analyze the controlling status of diabetes. All three studies showed that plasma glucose levels in severe patients were significantly higher than those in non-severe patients. Although such data did not present sufficient evidence, elevation of plasma glucose is likely to be associated with severity of COVID-19. Zhu et al performed a retrospective, multi-centered study of 7,337 cases of COVID-19 in Hubei Province, China, among which 952 had pre-existing type 2 diabetes \[[@R13]\]. They found that subjects with type 2 diabetes required more medical interventions, and had a significantly higher mortality (7.8% vs. 2.7%) and multiple organ injury than the non-diabetic individuals. Further, well-controlled blood glucose was associated with markedly lower mortality compared to individuals with poorly controlled blood glucose, supporting a significance of hyperglycemia in severe COVID-19.

###### Prevalence of Diabetes in COVID-19 Patients

                                   All patients      Severe patients   Non-severe patients   P value
  -------------------------------- ----------------- ----------------- --------------------- ----------
  Huang et al, 2020 \[[@R02]\]     8/41 (20%)        1/13 (8%)         7/28 (25%)            0.16
  Zhang et al, 2020 \[[@R03]\]     17/140 (12.1%)    8/58 (13.8%)      9/82 (11%)            0.615
  Wang et al, 2020 \[[@R04]\]      14/138 (10.1%)    8/36 (22.2%)      6/102 (5.9%)          0.009
  Wu et al, 2020 \[[@R05]\]        22/201 (10.9%)    16/84 (19%)       6/117 (5.1%)          0.002
  Zhou et al, 2020 \[[@R01]\]      36/191 (19%)      17/54 (31%)       19/137 (14%)          0·0051
  Wan et al, 2020 \[[@R06]\]       12/135 (8.9%)     9/40 (22.5%)      3/95 (3.1%)           NA
  Guan et al, 2020 \[[@R07]\]      30/1,590 (8.2%)   19/130 (14.6%)    80/1,460 (5.5%)       NA
  Wang et al, 2020 \[[@R08]\]      54/339 (16%)      11/65 (17.2%)     43/274 (15.8%)        0.116
  Chen et al, 2020 \[[@R9]\]       14/145 (9.7%)     7/43 (16.3%)      7/102 (6.9%)          0.08
  Hu et al, 2020 \[[@R10]\]        47/323 (14.6%)    11/26 (42.3%)     14/151 (9.3%)         \< 0.001
  Itelman et al, 2020 \[[@R11]\]   30/162 (18.5%)    11/92 (30.8%)     8/26 (12%)            0.04
  Huang et al, 2020 \[[@R12]\]     19/202 (9.4%)     8/23 (34.8%)      11/179 (6.1%)         \< 0.001

P values indicate a statistically significant difference between severe and non-severe patients. NA: not available; COVID-19: coronavirus disease 2019.

The prevalence of hypertension in all COVID-19 patients, severe and non-severe COVID-19 patients was shown in [Table 2](#T2){ref-type="table"} \[[@R01]-[@R12]\]. Five of 12 studies showed a statistically significantly higher prevalence of hypertension in severe patients than in non-severe patients. In the meta-analysis, the prevalence of hypertension in severe patients was significantly higher than that in non-severe patients (OR: 2.69, 95% CI: 2.16 - 3.34). Seven studies were available to analyze the controlling status of hypertension. Five studies did not show any difference in blood pressure between severe and non-severe patients. Huang et al showed that systolic blood pressure was significantly higher in severe patients than in non-severe patients \[[@R02]\]. Itelman et al showed that minimal systolic blood pressure was significantly lower in severe patients than in non-severe patients, and maximal systolic blood pressure was significantly higher in severe patients than in non-severe patients \[[@R11]\]. Blood pressure itself is unlikely to be associated with severity of COVID-19. Since hypertension is one of the most significant risk factors for severe disease and mortality in COVID-19, and angiotensin-converting enzyme (ACE) 2 is the entry receptor of SARS-CoV-2 \[[@R14], [@R15]\], the effects of ACE inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) in COVID-19 patients have received much focus. A recent study has shown the protective effects of ACEIs/ARBs against mortality in COVID-19 \[[@R16]\], challenging the association between ACEIs/ARBs use and severe COVID-19.

###### Prevalence of Hypertension in COVID-19 Patients

                                   All patients        Severe patients   Non-severe patients   P value
  -------------------------------- ------------------- ----------------- --------------------- ----------
  Huang et al, 2020 \[[@R02]\]     6/41 (15%)          2/13 (15%)        4/28 (14%)            0.93
  Zhang et al, 2020 \[[@R03]\]     42/140 (30%)        22/58 (37.9%)     20/82 (24.4%)         0.085
  Wang et al, 2020 \[[@R04]\]      43/138 (31.2%)      21/36 (58.3%)     22/102 (21.6%)        \< 0.001
  Wu et al, 2020 \[[@R05]\]        39/201 (19.4%)      23/84 (27.4%)     16/117 (13.7%)        0.02
  Zhou et al, 2020 \[[@R01]\]      58/191 (30%)        26/54 (48%)       32/137 (23%)          0·0008
  Wan et al, 2020 \[[@R06]\]       13/135 (9.6%)       4/40 (10%)        9/95 (9.4%)           NA
  Guan et al, 2020 \[[@R07]\]      269/1,590 (16.9%)   38/269 (14.1%)    61/1,321 (4.6%)       NA
  Wang et al, 2020 \[[@R08]\]      138/339 (40.8%)     32/65 (50%)       106/274 (38.8%)       0.031
  Chen et al, 2020 \[[@R9]\]       22/145 (15.2%)      9/43 (20.9%)      13/102 (12.7%)        0.21
  Hu et al, 2020 \[[@R10]\]        105/323 (32.5%)     10/26 (38.5%)     39/151 (25.8%)        0.056
  Itelman et al, 2020 \[[@R11]\]   49/162 (30.2%)      13/26 (50%)       18/92 (19.6%)         0.002
  Huang et al, 2020 \[[@R12]\]     29/202 (14.4%)      2/23 (8.7%)       27/179 (15.1%)        0.411

P values indicate a statistically significant difference between severe and non-severe patients. NA: not available; COVID-19: coronavirus disease 2019.

Why is hypertension one of the most significant risk factors for severe disease and mortality in COVID-19? Diabetes and hypertension are crucial coronary risk factors, and diabetes and hypertension are closely interlinked because of similar risk factors, such as endothelial dysfunction, vascular inflammation, arterial re-modelling, atherosclerosis, dyslipidemia, and obesity \[[@R17]\]. Common mechanisms, such as upregulation of the renin-angiotensin-aldosterone system, oxidative stress, inflammation, and activation of the immune system likely contribute to the close relationship between diabetes and hypertension \[[@R17]\]. High prevalence of diabetes and hypertension in severe COVID-19 patients can be explained by such vascular damage. The prevalence of cardiovascular disease (CVD) in all COVID-19 patients, severe and non-severe COVID-19 patients was shown in [Table 3](#T3){ref-type="table"} \[[@R01]-[@R08], [@R10]-[@R12]\]. Four of 11 studies showed a statistically significantly higher prevalence of CVD in severe patients than in non-severe patients. In the meta-analysis, the prevalence of CVD in severe patients was significantly higher than that in non-severe patients (OR: 5.37, 95% CI: 3.73 - 7.74). Further, CVD was significantly associated with increased odds of death (OR: 21.4) \[[@R01]\], supporting a significant association between vascular damage and severity of COVID-19.

###### Prevalence of Cardiovascular Disease in COVID-19 Patients

                                   All patients      Severe patients   Non-severe patients   P value
  -------------------------------- ----------------- ----------------- --------------------- -----------
  Huang et al, 2020 \[[@R02]\]     6/41 (15%)        3/13 (23%)        3/28 (11%)            0.32
  Zhang et al, 2020 \[[@R03]\]     7/140 (5%)        4/58 (6.9%)       3/82 (3.7%)           0.448
  Wang et al, 2020 \[[@R04]\]      20/138 (14.5%)    9/36 (25%)        11/102 (10.8%)        0.04
  Wu et al, 2020 \[[@R05]\]        8/201 (4%)        5/84 (6%)         3/117 (2.6%)          0.4
  Zhou et al, 2020 \[[@R01]\]      15/191 (8%)       13/54 (24%)       2/137 (1%)            \< 0.0001
  Wan et al, 2020 \[[@R06]\]       7/135 (5.2%)      6/40 (15%)        1/95 (1%)             NA
  Guan et al, 2020 \[[@R07]\]      59/1,590 (3.7%)   8/59 (13.6%)      91/1,531 (5.9%)       NA
  Wang et al, 2020 \[[@R08]\]      53/339 (14.2%)    21/65 (32.8%)     32/274 (11.7%)        \< 0.001
  Hu et al, 2020 \[[@R10]\]        41/323 (12.7%)    11/26 (42.3%)     8/151 (5.3%)          \< 0.001
  Itelman et al, 2020 \[[@R11]\]   12/162 (7.4%)     4/26 (15.4%)      5/92 (5.4%)           0.228
  Huang et al, 2020 \[[@R12]\]     5/202 (2.5%)      1/23 (4.3%)       4/179 (2.2%)          0.539

P values indicate a statistically significant difference between severe and non-severe patients. NA: not available; COVID-19: coronavirus disease 2019.

D-dimer is detected in injured vascular endothelium \[[@R18]\], and von Willebrand factor is produced by endothelial cells in response to injury, and high von Willebrand factor level has been observed in systemic vasculitis \[[@R19]\]. Multivariable regression showed increasing odds of in-hospital death associated with D-dimer greater than 1 µg/mL (OR: 18.42, 95% CI: 2.64 - 128.55; P = 0.0033) on admission \[[@R01]\]. Elevated von Willebrand factor levels were observed in COVID-19 patients in the intensive care unit \[[@R20]\]. D-dimer was also reported to be significantly increased in Kawasaki disease with coronary artery lesions, and to be the independent risk for coronary artery lesions in Kawasaki disease \[[@R21]\]. Von Willebrand factor parameters were reported to represent potential biomarkers for disease activity and coronary artery lesion in patients with Kawasaki disease \[[@R22]\]. A very recent article reported the development of Kawasaki disease in COVID-19 patient \[[@R23]\], supporting an association between endothelial injury and severe COVID-19.

In conclusion, endothelial injury may be associated with severity of COVID-19, which can partially explain high prevalence of diabetes and hypertension in severe COVID-19.
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